Beyond its activity in PDGFRA-mutant GISTs, avapritinib has also been explored in broader GIST populations, where its efficacy in targeting KIT mutations offers an additional treatment option, particularly for patients who have exhausted prior lines of TKI therapy [65]. The gene discussed is KIT; the disease is gastrointestinal stromal tumor.